These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 27528761)

  • 21. Bone morphogenetic protein-9 is a circulating vascular quiescence factor.
    David L; Mallet C; Keramidas M; Lamandé N; Gasc JM; Dupuis-Girod S; Plauchu H; Feige JJ; Bailly S
    Circ Res; 2008 Apr; 102(8):914-22. PubMed ID: 18309101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II.
    Kim JH; Peacock MR; George SC; Hughes CC
    Angiogenesis; 2012 Sep; 15(3):497-509. PubMed ID: 22622516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tmem100, an ALK1 receptor signaling-dependent gene essential for arterial endothelium differentiation and vascular morphogenesis.
    Somekawa S; Imagawa K; Hayashi H; Sakabe M; Ioka T; Sato GE; Inada K; Iwamoto T; Mori T; Uemura S; Nakagawa O; Saito Y
    Proc Natl Acad Sci U S A; 2012 Jul; 109(30):12064-9. PubMed ID: 22783020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the molecular regulation of endothelial BMP9 signalling complexes and implications for cardiovascular disease.
    Wood JH; Guo J; Morrell NW; Li W
    Biochem Soc Trans; 2019 Jun; 47(3):779-791. PubMed ID: 31127068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated circulating BMP9 aggravates pulmonary angiogenesis in hepatopulmonary syndrome rats through ALK1-Endoglin-Smad1/5/9 signalling.
    Yang C; Sun M; Yang Y; Han Y; Wu X; Wu X; Cao H; Chen L; Lei Y; Hu X; Chen Y; Zeng Z; Li J; Shu X; Yang Z; Lu K; Li Y; Wang X; Yi B
    Eur J Clin Invest; 2024 Aug; 54(8):e14212. PubMed ID: 38591651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10.
    Bouvard C; Tu L; Rossi M; Desroches-Castan A; Berrebeh N; Helfer E; Roelants C; Liu H; Ouarné M; Chaumontel N; Mallet C; Battail C; Bikfalvi A; Humbert M; Savale L; Daubon T; Perret P; Tillet E; Guignabert C; Bailly S
    Cardiovasc Res; 2022 Jun; 118(7):1805-1820. PubMed ID: 34086873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BMP9 (Bone Morphogenetic Protein-9)/Alk1 (Activin-Like Kinase Receptor Type I) Signaling Prevents Hyperglycemia-Induced Vascular Permeability.
    Akla N; Viallard C; Popovic N; Lora Gil C; Sapieha P; Larrivée B
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1821-1836. PubMed ID: 29880487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid Activation of Bone Morphogenic Protein 9 by Receptor-mediated Displacement of Pro-domains.
    Kienast Y; Jucknischke U; Scheiblich S; Thier M; de Wouters M; Haas A; Lehmann C; Brand V; Bernicke D; Honold K; Lorenz S
    J Biol Chem; 2016 Feb; 291(7):3395-410. PubMed ID: 26677222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Homozygous GDF2 nonsense mutations result in a loss of circulating BMP9 and BMP10 and are associated with either PAH or an "HHT-like" syndrome in children.
    Hodgson J; Ruiz-Llorente L; McDonald J; Quarrell O; Ugonna K; Bentham J; Mason R; Martin J; Moore D; Bergstrom K; Bayrak-Toydemir P; Wooderchak-Donahue W; Morrell NW; Condliffe R; Bernabeu C; Upton PD
    Mol Genet Genomic Med; 2021 Dec; 9(12):e1685. PubMed ID: 33834622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis.
    Scharpfenecker M; van Dinther M; Liu Z; van Bezooijen RL; Zhao Q; Pukac L; Löwik CW; ten Dijke P
    J Cell Sci; 2007 Mar; 120(Pt 6):964-72. PubMed ID: 17311849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of
    Hodgson J; Swietlik EM; Salmon RM; Hadinnapola C; Nikolic I; Wharton J; Guo J; Liley J; Haimel M; Bleda M; Southgate L; Machado RD; Martin JM; Treacy CM; Yates K; Daugherty LC; Shamardina O; Whitehorn D; Holden S; Bogaard HJ; Church C; Coghlan G; Condliffe R; Corris PA; Danesino C; Eyries M; Gall H; Ghio S; Ghofrani HA; Gibbs JSR; Girerd B; Houweling AC; Howard L; Humbert M; Kiely DG; Kovacs G; Lawrie A; MacKenzie Ross RV; Moledina S; Montani D; Olschewski A; Olschewski H; Ouwehand WH; Peacock AJ; Pepke-Zaba J; Prokopenko I; Rhodes CJ; Scelsi L; Seeger W; Soubrier F; Suntharalingam J; Toshner MR; Trembath RC; Vonk Noordegraaf A; Wort SJ; Wilkins MR; Yu PB; Li W; Gräf S; Upton PD; Morrell NW
    Am J Respir Crit Care Med; 2020 Mar; 201(5):575-585. PubMed ID: 31661308
    [No Abstract]   [Full Text] [Related]  

  • 32. Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations.
    Ricard N; Bidart M; Mallet C; Lesca G; Giraud S; Prudent R; Feige JJ; Bailly S
    Blood; 2010 Sep; 116(9):1604-12. PubMed ID: 20501893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Bone Morphogenetic Protein (BMP)-derived Peptide Based on the Type I Receptor-binding Site Modifies Cell-type Dependent BMP Signalling.
    Tong Z; Guo J; Glen RC; Morrell NW; Li W
    Sci Rep; 2019 Sep; 9(1):13446. PubMed ID: 31530856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood flow regulates acvrl1 transcription via ligand-dependent Alk1 activity.
    Anzell AR; Kunz AB; Donovan JP; Tran TG; Lu X; Young S; Roman BL
    Angiogenesis; 2024 Aug; 27(3):501-522. PubMed ID: 38727966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Large-scale phosphoproteomics reveals activation of the MAPK/GADD45β/P38 axis and cell cycle inhibition in response to BMP9 and BMP10 stimulation in endothelial cells.
    Al Tarrass M; Belmudes L; Koça D; Azemard V; Liu H; Al Tabosh T; Ciais D; Desroches-Castan A; Battail C; Couté Y; Bouvard C; Bailly S
    Cell Commun Signal; 2024 Mar; 22(1):158. PubMed ID: 38439036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1.
    Yao Y; Zebboudj AF; Shao E; Perez M; Boström K
    J Biol Chem; 2006 Nov; 281(45):33921-30. PubMed ID: 16950789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Homeobox D3, A Novel Link Between Bone Morphogenetic Protein 9 and Transforming Growth Factor Beta 1 Signaling.
    Wang L; Yao J; Yu T; Zhang D; Qiao X; Yao Z; Wu X; Zhang L; Boström KI; Yao Y
    J Mol Biol; 2020 Mar; 432(7):2030-2041. PubMed ID: 32061928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Modulating BMP9, BMPR2, and AQP1 on BMP Signaling in Human Pulmonary Microvascular Endothelial Cells.
    Lotsios NS; Keskinidou C; Dimopoulou I; Kotanidou A; Langleben D; Orfanos SE; Vassiliou AG
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.
    Bendell JC; Gordon MS; Hurwitz HI; Jones SF; Mendelson DS; Blobe GC; Agarwal N; Condon CH; Wilson D; Pearsall AE; Yang Y; McClure T; Attie KM; Sherman ML; Sharma S
    Clin Cancer Res; 2014 Jan; 20(2):480-9. PubMed ID: 24173543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activin receptor inhibitors--dalantercept.
    Gupta S; Gill D; Pal SK; Agarwal N
    Curr Oncol Rep; 2015 Apr; 17(4):14. PubMed ID: 25708802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.